Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
1.
Thromb Res ; 236: 155-160, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38452447

ABSTRACT

BACKGROUND: Tigecycline-associated hypofibrinogenemia has been reported as an important adverse effect in recent years, but controlled studies minimizing confounding factors are needed. The objective of our study was to assess changes in fibrinogen levels in patients for hospitalization, comparing two antibiotic episodes (tigecycline and other) within the same patients. METHODS: The retrospective, self-controlled case series study was conducted at our University Hospitals. The study compared the change in fibrinogen levels during the patient's hospitalization for tigecycline (TigePer) and another antibiotic period (OtherPer). In addition, bleeding events, bleeding risk (determined by the IMPROVE bleeding risk score), as well as 15- and 30-day mortality rates between TigePer and OtherPer were compared. RESULTS: The study enrolled 50 patients with 100 episodes of antibiotic treatment. The median age (interquartile range) of the patients was 68.5 (21.5) years, and 38 % were female. As compared to OtherPer, TigePer had a statistically significant reduction in fibrinogen levels (p < 0.001), with a hypofibrinogenemia rate of 40 % in TigePer as compared to 2 % in OtherPer (p < 0.001). TigePer demonstrated a significantly higher 15-day mortality rate (p = 0.006). No significant differences were observed between the two periods in terms of bleeding risk, rate of bleeding events, and 30-day mortality rate (p > 0.05). CONCLUSION: Hypofibrinogenemia and other coagulopathies, without associated bleeding events, are more frequently observed in patients receiving tigecycline. Therefore, it is crucial for clinicians to monitor fibrinogen levels during tigecycline use.


Subject(s)
Afibrinogenemia , Humans , Female , Aged , Male , Afibrinogenemia/chemically induced , Tigecycline/adverse effects , Fibrinogen/analysis , Retrospective Studies , Anti-Bacterial Agents/adverse effects , Hemorrhage/chemically induced , Hemorrhage/drug therapy
2.
J Investig Med ; 72(4): 349-358, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38328895

ABSTRACT

Compliance with guidelines in the empirical treatment for community-acquired pneumonia (CAP) is very important to increase treatment success and reduce mortality. This study aimed to determine compliance with guideline recommendations for CAP and define the role of the clinical pharmacist (CP). Patients diagnosed with CAP were evaluated retrospectively between January 2018 and January 2020 and prospectively between February 2020 and February 2021. Compliance with guidelines was evaluated according to the local, national (Turkish Thoracic Society), and international (American Thoracic Society and Infectious Disease Society of America, European Society of Clinical Microbiology and Infectious Diseases) guidelines. A total of 751 patients (423 in the retrospective and 328 in the prospective period) were included. It was determined that the 30-day mortality and length of stay were higher in patients who were not treated according to the guidelines. The compliance for empirical treatments was 16.3%-59.1% and 7.8%-30.1% in retrospective and prospective periods, respectively. During the prospective period, a total of 603 recommendations were made by CP, and 578 (95.9%) were accepted and implemented. In the prospective period, treatment duration was shortened, inappropriate fluoroquinolone use was decreased, the switch to oral treatment was increased, and the number of potential drug-drug interactions was decreased (p < 0.001). Compliance with guidelines is essential to be improved to reduce mortality, shorten the length of stay, determine the appropriate antimicrobial duration, and reduce the use of fluoroquinolones and broad-spectrum antibiotics unless necessary. CP intervention contributes to the rational selection of antimicrobials, limiting drug-drug interactions, avoiding toxicities, and compliance with guidelines.


Subject(s)
Community-Acquired Infections , Pneumonia , Humans , Retrospective Studies , Prospective Studies , Pneumonia/drug therapy , Pneumonia/diagnosis , Anti-Bacterial Agents/therapeutic use , Treatment Outcome , Community-Acquired Infections/drug therapy
3.
Int J Antimicrob Agents ; 63(2): 107035, 2024 Feb.
Article in English | MEDLINE | ID: mdl-37979889

ABSTRACT

OBJECTIVES: Nephrotoxicity is the most serious and common adverse effect that limits the use of polymyxins. This study compared polymyxin E (colistin) and polymyxin B regarding drug-related nephrotoxicity. METHODS: This study was conducted as a retrospective cohort study in a university hospital between January 2020 and July 2022. Patients older than 18 years and who received colistin or polymyxin B were identified using electronic hospital records. Kidney disease improving global outcome criteria were used for assessing nephrotoxicity. RESULTS: A total of 190 patients, 95 in both groups, were evaluated. The incidence of acute kidney injury during the treatment was higher in the colistin group [52.6% (n = 50) and 34.7% (n = 33), P = 0.013]. In patients who were exposed to high-dose, the rate of nephrotoxicity was higher in patients receiving colistin [25% (n = 3) vs. 76.9% (n = 10); P = 0.017]. Nephrotoxicity was reversible in 64.4% (n = 38) of patients and the reversibility rate was similar (70% and 52.6% for colistin and polymyxin; P = 0.248). In the multivariable analysis, colistin treatment [odds ratio (OR): 3.882, 95% confidence interval (95% CI) = (1.829-8.241)], concomitant vasopressor use (OR = 2.08, CI: 1.036-4.179), and age (OR=1.036, CI: 1.014-1.058) were found to be independent markers of nephrotoxicity. CONCLUSION: Nephrotoxicity was more common in patients receiving high-dose colistin than polymyxin B. Therefore, the use of appropriate doses of colistin is important in terms of preventing nephrotoxicity. In addition, advancing age and concomitant use of vasopressors contribute to polymyxin-related nephrotoxicity.


Subject(s)
Acute Kidney Injury , Polymyxin B , Humans , Polymyxin B/adverse effects , Colistin/adverse effects , Polymyxins/adverse effects , Anti-Bacterial Agents/adverse effects , Retrospective Studies , Acute Kidney Injury/epidemiology
4.
BMC Med Educ ; 23(1): 682, 2023 Sep 20.
Article in English | MEDLINE | ID: mdl-37730582

ABSTRACT

BACKGROUND: Postgraduate education programs in clinical pharmacy have become widespread in Türkiye. This study aimed to identify factors associated with the intention of Turkish clinical pharmacists and candidates (who were graduates and students of postgraduate clinical pharmacy programs) to provide pharmaceutical care. METHODS: This prospective observational study was conducted between June 2021 and May 2022. After searching relevant studies, an expert panel discussion, translation, cultural adaptation, and a pilot study developed a 52-item Turkish scale based on the Theory of Planned Behavior (TBP). Cronbach alpha for each construct was calculated after an explanatory factor and test-retest reliability analysis. An online survey link was sent to all graduates or candidates of postgraduate clinical pharmacy programs in Türkiye. After univariate regression analysis, the multiple linear regression model was performed. RESULTS: One hundred fifty-six participants completed the survey (response rate: 59.1%). The Cronbach's alpha for attitude (9 items), subjective norm (6 items), perceived behavioural control (5 items), self-efficacy (6 items), intention (11 items) and past behaviour (15 items) were 0.945, 0.720, 0.751, 0.864, 0.934 and 0.955 respectively. The multiple linear regression analysis found a higher score of the subjective norm (p = 0.016), a higher score of self-efficacy (p < 0.001), younger age (p < 0.001) and having PhD (p = 0.038) were associated with increased intention score. CONCLUSIONS: It was shown that higher self efficacy and positive beliefs of their peers and other healthcare professionals were associated with their higher intention score for providing pharmaceutical care. Younger age and having a PhD were other factors associated with their intention to provide pharmaceutical care.


Subject(s)
Pharmacists , Pharmacy Service, Hospital , Humans , Intention , Pilot Projects , Reproducibility of Results
5.
Prim Health Care Res Dev ; 23: e38, 2022 07 22.
Article in English | MEDLINE | ID: mdl-35866296

ABSTRACT

BACKGROUND: Healthcare professionals' vaccine recommendation is the most effective method to increase vaccination rates of the community. The vaccine counseling and recommendation behavior of pharmacists, who are among the easily accessible healthcare professionals, are influenced by their knowledge and attitudes about vaccines. AIM: It was aimed to investigate community pharmacists' knowledge, attitudes, and practices regarding commonly used vaccines. METHODS: A cross-sectional study was conducted as an online survey with a sample of 1100 community pharmacists in Turkey. Pharmacists were invited to participate in the study by phone calls. A structured survey, which consists of 40 questions to assess the knowledge, attitudes, and practices regarding vaccines, was sent to the e-mail addresses of pharmacists who volunteered to participate in the study. FINDINGS: A total of 430 pharmacists completed the survey. Thirty percent of pharmacists had lack of knowledge about vaccination during pregnancy, whereas 52.2% and 31.4% of pharmacists believed that tetanus and influenza vaccines should be provided during pregnancy, respectively. Nearly 89% of pharmacists recommended vaccines to patients, mainly for influenza vaccine (83.9%). Only 31.5% of pharmacists had been vaccinated against influenza in the last season, whereas 50.5% had never been vaccinated. Pharmacists who had been vaccinated with influenza vaccine had a high rate of recommending influenza vaccines to the patients. CONCLUSION: The present study found that vaccination among pharmacists in Turkey and their knowledge on vaccination during pregnancy were low. Further education of pharmacists to improve their knowledge and attitudes toward vaccines is needed.


Subject(s)
Influenza Vaccines , Cross-Sectional Studies , Female , Health Knowledge, Attitudes, Practice , Humans , Pharmacists/psychology , Pregnancy , Surveys and Questionnaires , Vaccination/psychology
6.
Postgrad Med ; 134(6): 635-640, 2022 Aug.
Article in English | MEDLINE | ID: mdl-35671079

ABSTRACT

OBJECTIVES: Despite the advances in antiretroviral treatment (ART), persistent inflammation remained a challenge. We analyzed the inflammatory-score changes through 2-years in people living with HIV (PLWH) treated with different antiretroviral regimes. METHODS: This study was conducted in Hacettepe University HIV/AIDS Treatment and Research Center. PLWH diagnosed between 2014 and 2020 were included. Inflammatory and metabolic markers (CD4/CD8 ratio, C-reactive protein (CRP), Systemic Inflammatory Index (SII), Neutrophil-Lymphocyte Ratio (NLR), Mean Platelet Volume (MPV), Platecrite (PCT), and Low-Density Lipoprotein/High-Density Lipoprotein (LDL/HDL), Platelet-to-Lymphocyte Ratio (PLR) and ARTs were captured from database through 2-years from the diagnosis. The 2-year change (Δ) in markers was calculated and compared by ART type (backbone and 3rd agent). Mann-Whitney-U test and T-test were used for statistical analysis. RESULTS: This study included 205 PLWH; 175 (85.4%) were male, and the mean age was 38.98 (±10.88) years. The number of PLWH with suppressed viremia (<40 HIV-RNA copies/ml) was 164 (80%) at the end of the second year. MPV increased significantly higher among PLWH receiving ABC/3TC compared to PLWH receiving TDF/FTC (p < 0.05). The CD4:CD8 ratio increased, and SII, NLR, LDL/HDL ratios decreased significantly among PLWH treated with integrase strand transfer inhibitors (INSTI) compared with protease inhibitors (PI) and Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) (p < 0.05). CONCLUSIONS: Integrase inhibitor treatment is related to favorable inflammatory marker profile among PLWH in the 2-year follow-up. A favorable inflammatory profile may, in turn, contribute to the prevention of non-communicable diseases (NCD) among PLWH. This study showed that simple, easy-to-calculate markers could be implemented to define ongoing inflammation among PLWH under suppressive ART.


Subject(s)
HIV Infections , HIV Integrase Inhibitors , Adult , Anti-Retroviral Agents/therapeutic use , Female , HIV Infections/drug therapy , HIV Integrase Inhibitors/therapeutic use , Humans , Inflammation/drug therapy , Male , Reverse Transcriptase Inhibitors/therapeutic use
7.
Curr Eye Res ; 47(1): 69-78, 2022 01.
Article in English | MEDLINE | ID: mdl-34252337

ABSTRACT

PURPOSE/AIM OF THE STUDY: Researchers have investigated glaucoma drainage devices in various in vitro experimental setups to overcome their disadvantages. In this study, it is aimed to perform in vitro analyses of glaucoma drainage devices that are actively utilized for glaucoma treatment. MATERIALS AND METHODS: A new in vitro experimental setup is constructed and the first outcomes of numerical simulations and experimental trials are shared. Firstly, an in vitro experimental setup is designed and simulated in ANSYS Fluent, then assembled/fabricated using microfluidic equipment. Secondly, computational fluid dynamics results are expressed as pressure losses through an Ahmed Valve implant, a Molteno drainage device, an Ex-Press implant for physiological flow rates. RESULTS: In the scope of this study, Ahmed Valve (valved), Molteno (non-valved), Ex-Press (orbital shunt) implants are examined numerically using computational fluid dynamics tools. Results are compared with in vitro studies of the proposed experimental setup. Poiseuille and Reynolds numbers versus pressure drop characteristics of tested glaucoma drainage devices are also obtained using in vitro microfluidic experimental setup. In the range of 1.6-2.5 µl/min, Ahmed Valve implant created an active and effective pressure drop of 5.6 to 12 mmHg. Ahmed Valve and Molteno showed similar characteristics in terms of Poiseuille and Reynolds numbers variations with pressure drop across implants. Ex-Press, opposing Molteno and Ahmed Valve gave a reciprocal correlation between pressure drop and Po. CONCLUSIONS: High resemblances of pressure drops between computational fluid dynamics results and in vitro microfluidic experimental results proved that the setup will be a better choice compared to syringe pump type setups for testing different glaucoma drainage devices at the same conditions. In conclusion, a new glaucoma drainage device should be equipped with a slimmer but larger end plate and a valve mechanism similar to Ahmed Valve in the perspective of intraocular pressure drop performance.


Subject(s)
Glaucoma Drainage Implants , Glaucoma/surgery , Intraocular Pressure/physiology , Microfluidics/methods , Models, Biological , Follow-Up Studies , Glaucoma/physiopathology , Humans , Tonometry, Ocular
9.
Ir J Med Sci ; 191(5): 2193-2200, 2022 Oct.
Article in English | MEDLINE | ID: mdl-34708289

ABSTRACT

BACKGROUND: Pneumococcal diseases (PN) and herpes zoster (HZ) are preventable infections in the adult population. AIMS: This study aimed to identify the vaccination rates at 1 year after pharmacist-led provision of information in the community. The objectives were to reveal the reasons for not being vaccinated and to determine opinions and awareness of PN and HZ vaccination among public. METHODS: A prospective study was conducted in five social and solidarity centres in Turkey. Participants were educated by a pharmacist about PN and HZ diseases, vaccinations and reimbursement status, respectively. All participants were followed by telephone 1 year after to determine their vaccination status. RESULTS: A total of 155 participants (72.9% male; mean age was 68.72 ± 9.04 years) were included. With respect to PN and HZ vaccines, it was found that 40% and 12.7% of participants knew about the respective vaccines. Following the pharmacist's educational session, 52.9% and 51.6% were willing to have the respective vaccine, but only 5.7% and 0.8% respectively got vaccinated 1 year after the educational session. Perceived disease severity, provision of information by a pharmacist, and reimbursement status of the vaccines were not associated with the vaccination rates. CONCLUSIONS: The public obtain information on vaccines from friends and family members, which may result in misinformation and inappropriate behaviour in vaccination. Although educational sessions provided by pharmacists did not increase the actual vaccination rates for PN and HZ, public willingness to vaccination has increased.


Subject(s)
Herpes Zoster Vaccine , Herpes Zoster , Pneumococcal Infections , Vaccines , Adult , Aged , Female , Herpes Zoster/epidemiology , Herpes Zoster/prevention & control , Herpes Zoster Vaccine/therapeutic use , Humans , Male , Middle Aged , Pharmacists , Pneumococcal Infections/prevention & control , Pneumococcal Vaccines/therapeutic use , Prospective Studies , Vaccination
10.
Turk J Pharm Sci ; 18(4): 517-526, 2021 09 01.
Article in English | MEDLINE | ID: mdl-34496559

ABSTRACT

Detecting drug-related problems (DRPs) is important in pharmaceutical care in for better therapeutic outcomes. Clinical pharmacists-led comprehensive medication management plays a crucial role in the rational use of drugs by preventing, identifying, and resolving DRPs. In this review, we aimed to determine the effect of interventions on patient outcomes performed by clinical pharmacists in Turkey. A systematic literature search was performed on PubMed, Google Scholar, EMBASE, Cochrane Library, and Turkish databases (ULAKBIM, Dergipark). The main categories were "clinical pharmacist", "intervention", and "Turkey". Two reviewers reviewed each article independently. Two independent reviewers screened all records and extracted data; disagreements were resolved through a consensus. Randomized controlled studies, pre- to post-intervention comparison studies, and cross-sectional studies including pharmacist-led interventions were included in the review. This review included 15 articles evaluating clinical pharmacist interventions. Ten studies (66.7%) focused on DRPs and pharmacist interventions to these problems, while the remaining 5 (33.3%) studies focused on patient education and adherence issues. Studies were conducted in oncology (33.3%), geriatrics (20.0%), chest diseases (13.3%), psychiatry (6.7%), cardiology (6.7%), and infectious diseases (6.7%) clinics. When results of studies are reviewed, most of the interventions were made at the prescriber level followed by the drug level and patient level. Problems were solved in 54.2-93.2% of DRPs, and adherence, patient knowledge, or skills were improved in most of the studies. Most of the studies were carried out within the scope of a postgraduate or doctorate thesis and yet various positive outcomes such as the prevention of side effects, increased quality of life, and decreased duration of hospital stay were observed with high positive rates of interventions, which indicate that other healthcare workers are ready to collaborate with the clinical pharmacists in Turkey.

11.
Turk J Med Sci ; 51(5): 2786-2788, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34392669

ABSTRACT

BACKGROUND: To the editor, Favipiravir (FVP) was developed against the influenza virus infection and licensed for the treatment of influenza in Japan [1]. In addition to influenza viruses, FVP demonstrates a broad-spectrum activity against many RNA viruses including Ebola, Lassa, rabies, and severe fever with thrombocytopenia [2]. FVP exhibited a comparable in vitro efficacy against SARS-CoV-2 with remdesivir in a cell culture model [3]. DISCUSSION: The authors would like to acknowledge the contributions of numerous physicians, nurses, and healthcare personnel of Hacettepe University's COVID-19 response team for their selfless efforts in follow-up and care of the patients. Authors declare that there is no conflict of interest.


Subject(s)
COVID-19 Drug Treatment , Influenza, Human , Humans , Uric Acid , Hypoxanthine Phosphoribosyltransferase , SARS-CoV-2 , Biomarkers
12.
Antimicrob Agents Chemother ; 65(9): e0062921, 2021 08 17.
Article in English | MEDLINE | ID: mdl-34152808

ABSTRACT

Antifungal stewardship (AFS) is recommended to reduce the inappropriate use of antifungal drugs. In this study, the role of AFS in providing appropriate antifungal therapy was evaluated. This study included three periods, consisting of observation, feedback/education, and daily AFS activities. In the observation period, the use of systemic antifungals was evaluated for a baseline measurement of appropriateness. In the second period, monthly meetings were organized to provide feedback and education to physicians regarding antifungal therapy and the rate of adherence to the clinical guidelines. In the final period, a clinical pharmacist participated in daily ward rounds to evaluate the appropriateness of the antifungal therapy. A scoring system for appropriateness was used for comparison between the three periods. Four hundred eighteen episodes of antifungal therapy were evaluated. Baseline demographics of patients were similar in all three periods for age, gender, and the number of comorbidities. The indications for antifungal use were for prophylaxis in 22.7%, Candida infections in 58.6%, and invasive mold infections in 18.7%. During the third period, 157 (78.9%) recommendations were made and 151 (96.2%) were accepted. The overall appropriateness of antifungal use increased significantly for prophylaxis (30.8%, 17.9%, and 46.3%; P = 0.046) and treatment of fungal diseases (27.8%, 32.4%, and 71.9%; P < 0.001) between the first, second, and third periods, respectively. The 30-day mortality was not significantly changed between the three periods (19%, 15.6%, and 27.5%; P = 0.050). Appropriateness in antifungal therapy can be augmented by the integration of an AFS program. A team-based evaluation of fungal infections and assessment of patients by a clinical pharmacist with a therapeutic perspective may help to increase the quality of antifungal therapy.


Subject(s)
Antifungal Agents , Mycoses , Antifungal Agents/therapeutic use , Humans , Mycoses/drug therapy , Pharmacists , Tertiary Care Centers
13.
Transpl Infect Dis ; 23(4): e13593, 2021 Aug.
Article in English | MEDLINE | ID: mdl-33655683

ABSTRACT

Tigecycline has been approved by the US (United States) Food and Drug Administration in a variety of complicated infections due to its broad-spectrum antibiotic activity. Following phase III trials, the product label was revised and acute pancreatitis was listed as an adverse effect. Its safety profile in special groups such as renal transplant patients is not exactly known. We report the first case of unintentional rechallenge of tigecycline induced pancreatitis in a renal transplant patient. Ten days following the renal transplantation, a 35-year-old patient presented to the clinic with acute rejection. He received anti-thymocyte globulin (ATG) and pulse steroid treatments for rejection. Following the treatment, he developed perianal cellulitis and tigecycline was started. Nine days following initiation of tigecycline he received thrombectomy for his incidental cardiac thrombus. One day after thrombectomy, he developed acute pancreatitis (AP). Thrombectomy was suspected to be the cause of AP. During hospitalization for transplant rejection, tigecycline was re-started for a newly developed complicated abdominal infection. On the third day of the tigecycline re-treatment, he developed a second episode of AP. Following tigecycline withdrawal, his symptoms resolved and serum pancreatic enzymes returned to normal, thus AP was ultimately attributed to tigecycline. This lethal side effect should be kept in mind while treating severe infections in renal transplant recipients.


Subject(s)
Kidney Transplantation , Pancreatitis , Acute Disease , Adult , Calcineurin Inhibitors/adverse effects , Graft Rejection/drug therapy , Graft Rejection/prevention & control , Humans , Immunosuppressive Agents , Kidney Transplantation/adverse effects , Male , Pancreatitis/chemically induced , Tigecycline
14.
Turk J Pediatr ; 63(6): 970-977, 2021.
Article in English | MEDLINE | ID: mdl-35023646

ABSTRACT

BACKGROUND: Medication errors are frequently seen in pediatric patients. Medication error studies on pediatric cases were found to not only be limited but also the collaboration of clinical pharmacists and physicians on this topic was not published in Turkey. This study aimed to identify drug-related problems, especially in antibiotics. METHODS: This study was a point prevalence study with pediatric inpatients that used at least one antibiotic at a pediatric tertiary care reference hospital on November 16, 2016. Medications of patients were evaluated by clinical pharmacists in terms of drug-related problems and by physicians in terms of correct indications. RESULTS: Eighty-nine hospitalized patients were using antibiotics at the time of the study. The median age was 42 months (range: 1-226 months), and 49 (55.1%) of the patients were male. Clinical pharmacists detected a total of 210 potential drug-drug interactions in 46 (51.7%) patients. Approximately 48.5% of the patients in pediatric wards and 52.4% of the patients in surgical wards had at least one potential drug-drug interaction. A total of 39 medication errors were identified in 36 patients` drug orders. Most of the errors (51.3%) were due to dosing and administration time errors (35.9%). The number of errors per patient in surgical services was higher (0.47) than the pediatric services (0.42). Forty-three percent of errors were antimicrobial-related, and 70.5% of them were classified as dosing errors. CONCLUSIONS: Evaluation of patients` drug usage by a clinical pharmacist in terms of drug-related problems such as drug interactions, side effects and prescribing errors leads to better pharmaceutical care.


Subject(s)
Drug-Related Side Effects and Adverse Reactions , Pharmacy Service, Hospital , Adolescent , Anti-Bacterial Agents/adverse effects , Child , Child, Preschool , Female , Humans , Infant , Male , Medication Errors , Pharmacists
17.
Int J Clin Pract ; 75(4): e13952, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33342028

ABSTRACT

OBJECTIVE: Lack of knowledge/awareness of people living with hepatitis B (PLH) often leads to misinformation and stigmatisation. This study aimed to assess the contribution of the clinical pharmacist (CP)-led education on knowledge of PLH about their disease. METHODS: This prospective, cross-sectional study was carried out between 1 October 2017 and 1 April 2018, at infectious disease and gastroenterology outpatient clinics in a university hospital. All PLH were interviewed face-to-face by a CP and a questionnaire about hepatitis B virus (HBV) knowledge was applied both at the beginning of the study (first interview) and 3 months later (second interview). Correct information was provided verbally to the patients by the CP concerning their incorrect answers during the first interview. A 10% increase in the number of correct answers was targeted for the second interview. RESULTS: A total of 147 PLH with a mean age of 43.05 ± 13.25 years were included in the study (55.8% female). In the first interview, the mean (±standard deviation) number of correct answers was 35.53 ± 9.15 out of 51 questions. In the second interview, correct answers were 48.67 ± 2.74 with an increase of 25.8% (P < .001). In the first interview, the number of correct answers was higher for the following groups: 20-39 age group, people with monthly income of >1081 $ and university graduates. The number of correct answers to all questions but one was elevated (P < .001) in the second interview. Answers to the question "there is a carrier state in chronic hepatitis B (CHB)" did not change (P = .125). CONCLUSION: Significant improvement was observed in the correct answer rate after CP's contribution, therefore as a team member, CP has an important role in improving patients' knowledge and attitude towards HBV infection.


Subject(s)
Hepatitis B , Pharmacists , Adult , Cross-Sectional Studies , Female , Health Knowledge, Attitudes, Practice , Humans , Male , Middle Aged , Prospective Studies , Surveys and Questionnaires
20.
Turk J Pharm Sci ; 17(3): 242-248, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32636699

ABSTRACT

OBJECTIVES: Coronavirus (COVID-19) cases and deaths related to the virus have been reported all over the world. Pharmacists play an important role in conveying accurate information about COVID-19 to the community. The aim of this study was to evaluate the knowledge and attitudes among hospital pharmacists about COVID-19. MATERIALS AND METHODS: A questionnaire was distributed to pharmacists participating in the 7th National Hospital and Institution Pharmacists Congress. The questions included in this questionnaire were created using the Turkish COVID-19 Scientific Committee guideline (COVID-19 Guideline). RESULTS: Analysis of 237 questionnaires (72.6% completed by women) showed that the media (television, newspaper), internet (nonscientific resources), internet (scientific resources), and social media were the most popular sources of information (60.3%, 53.6%, 53.2%, and 41.4%, respectively). The participants' age and the source of information that they used had an important influence on their knowledge of and attitudes towards COVID-19 infection. The majority of the participants (72.6%) stated that they were not wearing any kind of mask. Transmission of the disease by airborne route was well known by the participants (91.1%), as well as the main symptoms such as fever (92.4%), cough (84.4%), and dyspnea (60.3%). The participants were aware of the risk groups for COVID-19 infection such as advanced age (84.8%) and having comorbidities (80.2%). Washing hands with soap (92.0%), using hand disinfectants (80.6%), and avoiding contact with sick people (81.9%) were popular answers for protection from the disease, but wearing an N95 mask was also mentioned by 59.1% of the participants. Prevention of the disease by rinsing the nose with saline solution was believed in by 43.9% of the participants. CONCLUSION: Classical media and social media affect the attitudes of both the public and health professionals. Using media tools for accurate information is one of the basic conditions for preventing and controlling the spread of the disease.

SELECTION OF CITATIONS
SEARCH DETAIL
...